Altogether, finding new pathways of markers that affect the T-cell Exhaustion and regulate their expression besides PD-1 blocked therapy can provide new promising immunotherapeutic strategies in managing HCC. The gene discussed is RPL17; the disease is hepatocellular carcinoma.